Vergoeding 2019-2023 voor ATC-subgroep V03AE : Middelen bij hyperkaliemie en hyperfosfatemie
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| V03AE01 Polystyreensulfonzuur (na-zout ca-zout) (Sorbisterit ®) | 1.639.500 | 1.592.700 | 1.555.100 | 1.462.900 | 1.462.900 |
| V03AE02 Sevelameer (Renagel ®) | 2.956.700 | 2.790.800 | 2.366.000 | 2.370.500 | 2.289.200 |
| V03AE03 Lanthaancarbonaat (Fosrenol ®) | 3.653.400 | 3.677.900 | 3.467.800 | 3.482.600 | 3.186.000 |
| V03AE04 Calciumacetaat met magnesiumcarbonaat (Osvaren ®) | 77.003 | 81.002 | 77.873 | 78.202 | 80.591 |
| V03AE05 Ferrioxyhydroxide-sucrose-complex (Velphoro ®) | 591.810 | 575.600 | 562.420 | 534.090 | 556.040 |
| V03AE07 Calciumacetaat | 279 | 3.998 | 4.818 | 4.388 | 4.989 |
| V03AE09 Patiromeer calcium (Veltassa ®) | 15.752 | 114.130 | 229.970 | 349.570 | 385.990 |
| V03AE10 Natriumzirconiumcyclosilicaat (Lokelma ®) | . | . | 102.990 | 301.270 | 548.370 |
| Totaal | 8.934.444 | 8.836.130 | 8.366.971 | 8.583.520 | 8.514.080 |